Source: Sienna Biopharmaceuticals WESTLAKE VILLAGE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced top-line results from a Phase 2b study of SNA-120 (pegcantratinib), the Company’s lead drug candidate developed using its proprietary Topical by Design™ platform. This Phase 2b study, in mild-to-moderate…...
Telehealth firm 98point6 nets $50M in round led by Goldman Sachs
Source: FierceBiotech 98point6, a digital health company that makes primary care doctors available to patients over cellphone messages, raised $50 million in a new financing round led by Goldman Sachs. Its platform uses artificial intelligence to automate the tasks that don’t require direct physician interaction, such as gathering information on…...
Sanofi, Regeneron score positive Dupixent data in sinusitis as they await key FDA asthma verdict
Source: FiercePharma As the FDA gets set to decide whether Sanofi and Regeneron’s atopic dermatitis drug, Dupixent, can make a bid for asthma sales, the companies are churning out data in a variety of other conditions in hopes of boosting the product even more. The latest? Positive numbers from two phase 3 trials…...
UnitedHealth buys Genoa Healthcare, adding more than 400 pharmacies to its PBM
Source: FierceHealthcare With new competitors closing in, UnitedHealth is bolstering its defenses by purchasing Genoa Healthcare, the fifth-largest pharmacy chain in the country with 435 locations. Genoa—which also offers telepsychiatry services and medication management for behavioral health patients—will be absorbed by UnitedHealth’s pharmacy benefit manager OptumRx. According to its website,…...
Alexion snaps up another biotech, paying $1.2B for Syntimmune
Source: FierceBiotech Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune. The takeover gives Alexion control of SYNT001—a neonatal Fc receptor (FcRn) inhibitor in phase 1b/2a trials for patients with warm autoimmune hemolytic anemia (WAIHA) and pemphigus vulgaris (PV)…...
DOJ clears Cigna’s planned acquisition of Express Scripts
Source: FierceHealthcare The Department of Justice has given the green light to insurance giant Cigna Corp.'s planned $67 billion acquisition of pharmacy benefit manager Express Scripts. The move terminates the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, one of the conditions necessary to close the deal, officials said in…...
Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline
Source: Allergan DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will…...
Cigna, Express Scripts shareholders approve $67B deal
Source: FierceHealthcare Shareholders with both Cigna and Express Scripts voted to approve the insurer’s $67 billion acquisition of the PBM, the companies announced on Friday. The shareholder approval marks an important hurdle in finalizing the deal and follows several weeks in which Cigna tussled with activist investor Carl Icahn, momentarily…...
Allergan preludes major selloffs with $650M Almirall dermatology sale
Source: FiercePharma Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land. Spain’s Almirall said Friday it had agreed to pick up a portfolio of medical dermatology products from the Dublin drugmaker for up to $650 million in cash,…...
Bayer sells prescription dermatology brands to Denmark’s Leo Pharma
Source: Reuters FRANKFURT (Reuters) - Bayer has agreed to sell its established prescription dermatology brands to Denmark’s Leo Pharma, as the German drugmaker focuses on integrating seed maker Monsanto and on bolstering its drug development pipeline. The portfolio to be sold includes prescription skin creams against acne, fungal skin infections…...